Understanding Semaglutide
Semaglutide is a GLP-1 receptor agonist available in different finished pharmaceutical formulations. Injectable products such as Wegovy and Ozempic have product-specific schedules, while oral formulations such as Rybelsus and oral Wegovy have separate instructions.
Compound Name
Semaglutide
Compound Type
GLP-1 receptor agonist
Primary Research Area
Weight management and metabolic health
Injectable Formulations
Wegovy and Ozempic
Oral Formulations
Rybelsus and oral Wegovy
Regulatory Context
Approved finished medicines are available, with product-specific indications and prescribing requirements.
Formulation Matters
Injectable and oral semaglutide products are not interchangeable. Their dose schedules, administration instructions and product labels must be considered separately. Research-vial calculations do not establish equivalence to an approved finished medicine.
Semaglutide Dosing Schedules
The following are product-specific schedules described in the reference. They are not interchangeable dosing instructions. The relevant prescription and approved product label take priority.
SC example
Per administration
Frequency
Daily total
Reported cycle
Wegovy Injectable
0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg, with four-week stages
Once weekly
Not applicable — weekly injection
Four-week stages during escalation
Ozempic Injectable
0.25 mg → 0.5 mg; optional subsequent 1 mg or 2 mg stages, depending on product-specific instructions
Once weekly
Not applicable — weekly injection
Product-specific intervals; the reference describes optional later dose stages.
Oral Semaglutide
Oral Wegovy: 1.5 mg → 4 mg → 9 mg → 25 mg at 30-day stages. Rybelsus example: 3 mg → 7 mg → 14 mg.
Once daily
Product-specific daily oral amount
Oral Wegovy: 30-day stages; Rybelsus: product-specific escalation
Per administration
0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg, with four-week stages
Daily total
Not applicable — weekly injection
Reported cycle
Four-week stages during escalation
Per administration
0.25 mg → 0.5 mg; optional subsequent 1 mg or 2 mg stages, depending on product-specific instructions
Daily total
Not applicable — weekly injection
Reported cycle
Product-specific intervals; the reference describes optional later dose stages.
Per administration
Oral Wegovy: 1.5 mg → 4 mg → 9 mg → 25 mg at 30-day stages. Rybelsus example: 3 mg → 7 mg → 14 mg.
Daily total
Product-specific daily oral amount
Reported cycle
Oral Wegovy: 30-day stages; Rybelsus: product-specific escalation
The reference also describes an optional adult-only Wegovy 7.2 mg stage after at least four tolerated weeks at 2.4 mg. This is not a universal maximum or a schedule for every semaglutide product.
Follow the Specific Product Label
Wegovy, Ozempic, oral Wegovy and Rybelsus have different product instructions. Do not transfer doses between products or use research-vial calculations as a substitute for prescription instructions.
Semaglutide Safety Considerations
Semaglutide has important gastrointestinal and metabolic safety considerations. Product contraindications, medical history and concurrent medicines should be reviewed before treatment.
Semaglutide Storage and Product Handling
Approved Product Storage
Follow the storage instructions supplied with the specific approved finished product.
Formulation Differences
Injectable pens and oral tablets have different product requirements and administration instructions.
Research-Vial Stability
No generic research-vial shelf life is established. Approved product storage instructions should not be transferred to independently sourced research formulations.
Product Verification
Verify the exact product, strength, packaging and manufacturer instructions. Do not assume that a research-vial product is equivalent to an approved Wegovy or Ozempic formulation.
Semaglutide Concentration Calculator
The reference includes independently calculated examples using assumed amounts and final volumes. These are mathematical examples only, not preparation or administration instructions for approved semaglutide medicines.
Amount (mg)
Final volume (mL)
Concentration (mg/mL)
Per 1 U (mcg)
Per 10 U (mcg)
5
1
5 mg/mL
50 mcg
500 mcg
10
2
5 mg/mL
50 mcg
500 mcg
Concentration (mg/mL)
5 mg/mL
Concentration (mg/mL)
5 mg/mL
Source examples: 5 mg / 1 mL = 5 mg/mL; 10 mg / 2 mL = 5 mg/mL; 10 mg / 1 mL = 10 mg/mL; 30 mg / 3 mL = 10 mg/mL; 5 mg / 2 mL = 2.5 mg/mL. U means a U-100 volume marking: 1 U = 0.01 mL. These calculations do not establish sterility, stability, compatibility or suitability for injection. Approved finished medicines must be used according to their own product instructions.
Semaglutide Clinical Findings
Semaglutide has an established clinical history across specific approved indications and formulations. However, results from injectable and oral products must be interpreted according to their individual studies and approved uses.
Established GLP-1 Research
Semaglutide has been studied extensively as a GLP-1 receptor agonist in metabolic and weight-management research.
Multiple Approved Formulations
Injectable and oral formulations have separate clinical development programs and product-specific administration instructions.
Product-Specific Evidence
Evidence for one formulation or indication should not automatically be transferred to another product, route or research-vial preparation.
Semaglutide Regulatory Status
Approved Finished Medicines
Semaglutide is available in approved finished medicines, including specific Wegovy, Ozempic and Rybelsus products in relevant markets. Approval, indications, strengths and instructions vary by product and country. Research-vial semaglutide is not automatically equivalent to an approved pharmaceutical formulation.
Educational information only. Not medical advice, diagnosis or treatment guidance. Always follow the relevant approved product label and consult a qualified healthcare professional before making treatment decisions.
